Session

IBD (Posters)

A PILOT FEASIBILITY STUDY OF A NOVEL WHOLE-FOOD, SULPHIDE-REDUCING (5-SURE) DIET STRATEGY FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH AN ULCERATIVE-COLITIS POUCH
A PILOT FEASIBILITY STUDY OF A NOVEL WHOLE-FOOD, SULPHIDE-REDUCING (5-SURE) DIET STRATEGY FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH AN ULCERATIVE-COLITIS POUCH

IBD (Posters)  et al.

RISKOF CERVICAL CANCER IN INCIDENT ULCERATIVE COLITIS: A NATIONWIDE POPULATION-BASED STUDY SPANNING 10 YEARS
RISKOF CERVICAL CANCER IN INCIDENT ULCERATIVE COLITIS: A NATIONWIDE POPULATION-BASED STUDY SPANNING 10 YEARS

IBD (Posters)  et al.

VISCERAL OBESITY, DEFINED ACCORDING TO THE ANTHROPOMETRIC CRITERIA, IS NOT ASSOCIATED WITH A WORSE INFLAMMATORY BOWEL DISEASE COURSE AND DOES NOT LEAD TO AN ADDITIONAL INCREASE IN PROINFLAMMATORY RESPONSE
VISCERAL OBESITY, DEFINED ACCORDING TO THE ANTHROPOMETRIC CRITERIA, IS NOT ASSOCIATED WITH A WORSE INFLAMMATORY BOWEL DISEASE COURSE AND DOES NOT LEAD TO AN ADDITIONAL INCREASE IN PROINFLAMMATORY RESPONSE

IBD (Posters)  et al.

METABOLIC ASSOCIATED LIVER DISEASE AND SEX AS KEY FACTORS OF CARDIOVASCULAR RISK IN INFLAMMATORY BOWEL DISEASE
METABOLIC ASSOCIATED LIVER DISEASE AND SEX AS KEY FACTORS OF CARDIOVASCULAR RISK IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

A SYSTEMATIC REVIEW ON CLINICAL OUTCOMES IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
A SYSTEMATIC REVIEW ON CLINICAL OUTCOMES IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

PSYCHOLOGICAL INTERVENTIONS IMPROVE OUTCOMES IN INFLAMMATORY DIGESTIVE SYSTEM DISEASES. A META-ANALYSIS
PSYCHOLOGICAL INTERVENTIONS IMPROVE OUTCOMES IN INFLAMMATORY DIGESTIVE SYSTEM DISEASES. A META-ANALYSIS

IBD (Posters)  et al.

FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB – A TRANSITION LEADING TO CHANGES?
FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB – A TRANSITION LEADING TO CHANGES?

IBD (Posters)  et al.

LINKING LOCATION SPECIFIC GENE EXPRESSION PATTERNS TO POTENTIAL VEDOLIZUMAB OUTCOMES IN CROHN’S DISEASE PATIENTS
LINKING LOCATION SPECIFIC GENE EXPRESSION PATTERNS TO POTENTIAL VEDOLIZUMAB OUTCOMES IN CROHN’S DISEASE PATIENTS

IBD (Posters)  et al.

EVALUATION OF ACUTE INFLAMMATORY AND STRUCTURAL CHANGES OF SACROILIITIS ON MR ENTEROGRAPHY: A DIRECT COMPARISON WITH SACROILIAC JOINT MRI
EVALUATION OF ACUTE INFLAMMATORY AND STRUCTURAL CHANGES OF SACROILIITIS ON MR ENTEROGRAPHY: A DIRECT COMPARISON WITH SACROILIAC JOINT MRI

IBD (Posters)  et al.

CROHN'S DISEASE (CD): THE PREDICTIVE VALUE OF MONTREAL CLINICAL PATTERNS, AND BIOLOGICAL TREATMENT IN A LATIN AMERICAN IBD REFERENCE CENTER
CROHN'S DISEASE (CD): THE PREDICTIVE VALUE OF MONTREAL CLINICAL PATTERNS, AND BIOLOGICAL TREATMENT IN A LATIN AMERICAN IBD REFERENCE CENTER

IBD (Posters)  et al.

NATURAL HISTORY AND IMPACT OF IBS-TYPE SYMPTOMS IN INFLAMMATORY BOWEL DISEASE DURING 6 YEARS OF LONGITUDINAL FOLLOW-UP
NATURAL HISTORY AND IMPACT OF IBS-TYPE SYMPTOMS IN INFLAMMATORY BOWEL DISEASE DURING 6 YEARS OF LONGITUDINAL FOLLOW-UP

IBD (Posters)  et al.

STEROID USE IN A HIGH PROPORTION OF IBD PATIENTS – FIRST RESULTS FROM THE GERMAN COHORT OF THE IBD-DICE STUDY
STEROID USE IN A HIGH PROPORTION OF IBD PATIENTS – FIRST RESULTS FROM THE GERMAN COHORT OF THE IBD-DICE STUDY

IBD (Posters)  et al.

CHARACTERISTICS AND IMPACT OF ANXIETY AND DEPRESSION TRAJECTORIES IN INFLAMMATORY BOWEL DISEASE
CHARACTERISTICS AND IMPACT OF ANXIETY AND DEPRESSION TRAJECTORIES IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

FACTORS ASSOCIATED WITH RESECTION IN ISOLATED ILEAL CROHN’S DISEASE IN AN ASIAN COHORT
FACTORS ASSOCIATED WITH RESECTION IN ISOLATED ILEAL CROHN’S DISEASE IN AN ASIAN COHORT

IBD (Posters)  et al.

AN OPTIMIZATION OF INFLAMMATORY BOWEL DISEASES DIAGNOSIS USING AN ARTIFICIAL INTELLIGENCE
AN OPTIMIZATION OF INFLAMMATORY BOWEL DISEASES DIAGNOSIS USING AN ARTIFICIAL INTELLIGENCE

IBD (Posters)  et al.

COMPARATIVE ANALYSIS OF ORIGINATOR VERSUS BIOSIMILAR COUNTERPARTS WHEN TREATING ULCERATIVE COLITIS
COMPARATIVE ANALYSIS OF ORIGINATOR VERSUS BIOSIMILAR COUNTERPARTS WHEN TREATING ULCERATIVE COLITIS

IBD (Posters)  et al.

USTEKINUMAB PERSISTENCE IN THE TREATMENT OF CROHN’S DISEASE, FISTULIZING CROHN’S DISEASE AND ULCERATIVE COLITIS
USTEKINUMAB PERSISTENCE IN THE TREATMENT OF CROHN’S DISEASE, FISTULIZING CROHN’S DISEASE AND ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

IBD (Posters)  et al.

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

IBD (Posters)  et al.

QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

IBD (Posters)  et al.

Item 421 - 440 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
22
23 24 25 26 27 28 29 30 31